He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data forthcoming at a future meeting for ASCENT-03 in PD-L1 negative patients. Plus, a brain cancer cell therapy program, Gilead's partnership with Arcus on TIGIT, and the company's deal appetite.
View all episodes
By BiotechTV
4.3
66 ratings
He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data forthcoming at a future meeting for ASCENT-03 in PD-L1 negative patients. Plus, a brain cancer cell therapy program, Gilead's partnership with Arcus on TIGIT, and the company's deal appetite.
3,223 Listeners
1,902 Listeners
123 Listeners
324 Listeners
61 Listeners
9,960 Listeners
86 Listeners
34 Listeners
353 Listeners
19 Listeners
60 Listeners
514 Listeners
41 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners
46 Listeners